News List

Monday January 11, 2010 The Institut Curie and IPSOGEN sign a scientific collaboration agreement relating to the Genomic Grade, a molecular diagnostic tool for breast cancer

Paris, Marseille, January 11, 2010 - The INSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of a scientific collaboration agreement in the breast cancer domain. Within the framework of this project, the...

Category: Breast Cancer

Monday December 21, 2009 Institut Paoli Calmettes and IPSOGEN presented a new study supporting the pivotal role of tumor grade in chemotherapy prescription at the 32nd Annual San Antonio Breast Cancer Symposium

The study reinforces tumor grade as the most contributive factor for adjuvant chemotherapy in N-/M- IBC, together with tumor size

Category: Breast Cancer

Friday July 10, 2009 Ipsogen reports incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer

The St Gallen Consensus Meeting specifies that Genomic Grade could be considered as an adjunct to histological grading

Category: Breast Cancer

Thursday May 07, 2009 Ipsogen launches a new test to guide hormonotherapy prescription in breast cancer

The Genomic HR test will help pathologists to identify endocrine-responsive tumors that should benefit from hormonotherapy

Category: Breast Cancer

Sunday November 23, 2008 Ipsogen launches a new test to determine tumor HER2 status and guide Herceptin® prescription in breast cancer

Ipsogen’s HER2 test further strengthens the rapidly expanding MapQuant Dx™ platform, a microarray-based comprehensive solution designed to guide therapy decisions in breast cancer.

Category: Breast Cancer

Friday May 30, 2008 Ipsogen launches MapQuant Dx™ Genomic Grade test to identify breast cancer patients who benefit from chemotherapy

IPSOGEN SA (Marseilles, France and New Haven, CT, USA), a cancer profiler that markets molecular diagnostic assays for leukaemia announced today that it is entering the breast cancer diagnostic market with the European launch of...

Category: Breast Cancer

Monday May 19, 2008 Ipsogen announces three studies at the American Society of Clinical Oncology (ASCO) meeting extending the utility of the Genomic Grade index for predicting response to chemotherapy in breast cancer

IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced today that researchers from the University of Texas MD Anderson Cancer Center...

Category: Breast Cancer

Tuesday January 08, 2008 Ipsogen licenses the Genomic Grade™ to improve Breast Cancer diagnosis & treatment decision

IPSOGEN SAS, a leading molecular diagnostic company based in France and Connecticut, USA announced today the signature of a license agreement with Université Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive...

Category: Breast Cancer

Tuesday August 28, 2007 Affymetrix and Ipsogen collaborate to develop and market in-vitro diagnostic cancer tests

Affymetrix Inc. (Nasdaq: AFFX) and IPSOGEN, a leading molecular diagnostic company based in France and Connecticut, today announced that they have signed a Powered by Affymetrix™ (PbA) agreement. With this agreement, IPSOGEN...

Category: Breast Cancer

Thursday May 24, 2007 Ipsogen is part of COBRED, a breast & colon cancer biomarker European project.

Marseille, France, May 24, 2007 – IPSOGEN today announced that COBRED project coordinated by BioSystems International (Paris) has been awarded a 2.9 M€ grant as part of the 6th Framework Programme.

COBRED project aims at...

Category: Breast Cancer